Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;40(34):3952–3964. doi: 10.1200/JCO.22.01003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Investigator-assessed PFS in subgroups in the ITT population. The vertical gray band corresponds to the 95% CI of the ITT population. ^aExcludes patients with unknown race. ^bOne rucaparib-treated patient had an ECOG PS of 1 at screening and 2 at cycle 1 day 1. BRCA, BRCA1 or BRCA2; CA-125, cancer antigen 125; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; HRD, homologous recombination deficiency; ITT, intent-to-treat; LOH, loss of heterozygosity; PFS, progression-free survival; PR, partial response.

HHS Vulnerability Disclosure